KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Research & Development: 2009-2024

Historic Research & Development for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $998.0 million.

  • Teva Pharmaceutical Industries' Research & Development rose 6.67% to $256.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $994.0 million, marking a year-over-year increase of 1.64%. This contributed to the annual value of $998.0 million for FY2024, which is 4.72% up from last year.
  • According to the latest figures from FY2024, Teva Pharmaceutical Industries' Research & Development is $998.0 million, which was up 4.72% from $953.0 million recorded in FY2023.
  • Teva Pharmaceutical Industries' 5-year Research & Development high stood at $998.0 million for FY2024, and its period low was $838.0 million during FY2022.
  • Its 3-year average for Research & Development is $929.7 million, with a median of $953.0 million in 2023.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Research & Development dropped by 13.34% in 2022 and then rose by 13.72% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Research & Development (Yearly) stood at $997.0 million in 2020, then decreased by 3.01% to $967.0 million in 2021, then declined by 13.34% to $838.0 million in 2022, then grew by 13.72% to $953.0 million in 2023, then rose by 4.72% to $998.0 million in 2024.